New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Chrissy Teigin is the new face of Sanofi’s diabetes campaign. 1 The educational campaign is called Screen for Type 1, and it ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical ...

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...